Search

Carbidopa

It potently inhibits aromatic amino acid decarboxylase (DDC) and due to its chemical properties, it does not cross the blood-brain barrier. … therapy developed by Mayne Pharma in 1992.

Mometasone furoate

It has a glucocorticoid receptor binding affinity 22 times stronger than [dexamethasone] and higher than many other corticosteroids as well[A176906].

Aluminum chlorohydrate

It is included up to 25% in over-the-counter hygiene products as an active antiperspirant agent. … It is also used as a coagulant in the water purification process.

Glyburide

[L8123] It is typically given to patients who cannot be managed with the standard first line therapy, [metformin]. … [A183617] Glyburide was granted FDA approval on 1 May 1984.[L8117] A formulation with metformin was granted FDA approval on on 31 July 2000.[L8120]

Camizestrant

[L64117,L64107,L64116] It is the first next-generation oral SERD and complete ER antagonist approved in the first-line setting, and the only one approved for use with all three widely approved CDK4/6 inhibitors … [L64094,L64107] Patients are selected for treatment on the basis of an *ESR1* mutation detected by circulating tumor DNA testing during first-line endocrine therapy, before radiographic disease progression

Adalimumab

[A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA.[A39983] This drug is frequently known as _Humira_. … It is produced by recombinant DNA technology using a mammalian cell expression system.

Dinutuximab

neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. … Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse.

Tilidine

Medrogestone

It was conceived as an alternative for an orally effective contraceptive option.[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing. … [L1118] It was never approved by the FDA.

Dextran

It is administered by intravenous infusion. Dextran 75 is a complex branched glucan with an average molecular weight 75000 Daltons. … [T121] Dextran 40 is a sterile, nonpyrogenic preparation of low molecular weight dextran (average mol. wt. 40,000) in 5% Dextrose Injection or 0.9% Sodium Chloride Injection.